Baclofen FDA-Approved Indications
Baclofen is FDA-approved specifically for the treatment of spasticity resulting from multiple sclerosis and spinal cord injuries or diseases, particularly for relief of flexor spasms, concomitant pain, clonus, and muscular rigidity. 1
Primary FDA-Approved Indications
According to the FDA drug label, baclofen tablets are indicated for:
- Spasticity from multiple sclerosis - particularly effective for flexor spasms, pain, clonus, and muscular rigidity
- Spasticity from spinal cord injuries and other spinal cord diseases
The FDA label explicitly states that patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. 1
Important Exclusions and Non-Approved Uses
Baclofen is NOT FDA-approved for:
- Skeletal muscle spasm from rheumatic disorders - explicitly excluded from FDA indications 1
- Stroke - efficacy has not been established and is not recommended 1
- Cerebral palsy - efficacy has not been established and is not recommended 1
- Parkinson's disease - efficacy has not been established and is not recommended 1
This is particularly important because stroke guidelines 2 mention oral baclofen as a treatment option for post-stroke spasticity, but this represents off-label use that contradicts the FDA label's explicit statement that efficacy in stroke has not been established. 1
Intrathecal Baclofen
Intrathecal baclofen received FDA approval in 1996 for severe spasticity of spinal origin (including traumatic brain injury) in patients who are unresponsive to or intolerant of oral baclofen therapy. 3, 4 The original FDA approval was specifically for patients at least one year post-injury, though clinical practice has evolved to include earlier use in select cases. 3
Off-Label Uses (Not FDA-Approved)
While not FDA-approved, baclofen has extensive off-label use for:
- Alcohol use disorder - particularly for maintaining abstinence in patients with alcoholic liver disease 5, 6
- Post-stroke spasticity - despite lack of FDA approval for this indication 2, 7, 8
The evidence for alcohol use disorder shows baclofen may effectively maintain abstinence, particularly in patients with liver cirrhosis 5, 6, but this remains an off-label indication requiring careful consideration of the risk-benefit profile.
Clinical Caveats
- Baclofen has not significantly benefited stroke patients and these patients have shown poor tolerability according to the FDA label 1
- The drug should be used with caution in patients with impaired renal function as it is primarily excreted unchanged through the kidneys 1
- Abrupt withdrawal can cause hallucinations and seizures, requiring slow dose reduction when discontinuing 1